Ropinirole hydrochloride CR is a Small Molecule owned by Hisamitsu Pharmaceutical Co, and is involved in 6 clinical trials, which were completed.

Ropinirole acts as dopamine receptors D3 and D2 agonist stimulate these receptors in the striatum. It alleviates the dopamine deficiency which characterizes Parkinson's disease by stimulating striatal dopamine receptors. Ropinirole influences striatal neuronal firing rates by activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.

The revenue for Ropinirole hydrochloride CR is expected to reach a total of $967m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ropinirole hydrochloride CR NPV Report.

Ropinirole hydrochloride CR is currently owned by Hisamitsu Pharmaceutical Co. Kyowa Kirin is the other company associated in development or marketing of Ropinirole hydrochloride CR.

Ropinirole hydrochloride CR Overview

Ropinirole hydrochloride (Haruropi) is an indoline derivative, acts as an anti-Parkinson agent. It is formulated as controlled release tape for transdermal application. Ropinirole hydrochloride is indicated for the treatment of Parkinson's disease.

It was also under development for the treatment of idiopathic restless legs syndrome.

Kyowa Kirin Overview

Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY352,246 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 17%, compared to an operating margin of 15.9% in FY2020. In FY2021, the company recorded a net margin of 14.9%, compared to a net margin of 14.8% in FY2020. The company reported revenues of JPY98,504 million for the third quarter ended September 2022, an increase of 1% over the previous quarter.

Quick View – Ropinirole hydrochloride CR

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Ropinirole hydrochloride CR
Administration Pathway
  • Transdermal
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.